Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks

OBJECTIVE: To evaluate the efficacy and safety of golimumab 50 and 100 mg monotherapy in Japanese patients with active rheumatoid arthritis (RA) despite treatment with disease-modifying antirheumatic drugs (DMARDs). METHODS: A total of 316 patients were randomised to receive subcutaneous injections...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Tsutomu, Harigai, Masayoshi, Tanaka, Yoshiya, Yamanaka, Hisashi, Ishiguro, Naoki, Yamamoto, Kazuhiko, Miyasaka, Nobuyuki, Koike, Takao, Kanazawa, Minoru, Oba, Takuya, Yoshinari, Toru, Baker, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756456/
https://www.ncbi.nlm.nih.gov/pubmed/22984173
http://dx.doi.org/10.1136/annrheumdis-2012-201796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756456/
https://www.ncbi.nlm.nih.gov/pubmed/22984173
http://dx.doi.org/10.1136/annrheumdis-2012-201796

Ejemplares similares